Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4
Journal
Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
30
07
2019
accepted:
15
01
2021
pubmed:
3
3
2021
medline:
22
9
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Peptide-major histocompatibility complex (pMHC) multimers enable the detection of antigen-specific T cells in studies ranging from vaccine efficacy to cancer immunotherapy. However, this technology is unreliable when applied to pMHC class II for the detection of CD4
Identifiants
pubmed: 33649568
doi: 10.1038/s41587-021-00836-4
pii: 10.1038/s41587-021-00836-4
doi:
Substances chimiques
CD4 Antigens
0
HLA Antigens
0
Histocompatibility Antigens Class II
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
958-967Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Seder, R. A. & Ahmed, R. Similarities and differences in CD4
pubmed: 12942084
doi: 10.1038/ni969
Jonsson, P. et al. Remarkably low affinity of CD4/peptide–major histocompatibility complex class II protein interactions. Proc. Natl Acad. Sci. USA 113, 5682–5687 (2016).
pubmed: 27114505
pmcid: 4878507
doi: 10.1073/pnas.1513918113
Xiong, Y., Kern, P., Chang, H. & Reinherz, E. T cell receptor binding to a pMHCII ligand is kinetically distinct from and independent of CD4. J. Biol. Chem. 276, 5659–5667 (2001).
pubmed: 11106664
doi: 10.1074/jbc.M009580200
Davis, S. J. et al. The nature of molecular recognition by T cells. Nat. Immunol. 4, 217–224 (2003).
pubmed: 12605231
doi: 10.1038/ni0303-217
Garcia, K. C. et al. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 384, 577–581 (1996).
pubmed: 8955273
doi: 10.1038/384577a0
Wyer, J. R. et al. T cell receptor and coreceptor CD8α bind peptide–MHC independently and with distinct kinetics. Immunity 10, 219–225 (1999).
pubmed: 10072074
doi: 10.1016/S1074-7613(00)80022-9
Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996).
pubmed: 8810254
doi: 10.1126/science.274.5284.94
Meyer, A. L. et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc. Natl Acad. Sci. USA 97, 11433–11438 (2000).
pubmed: 11005833
pmcid: 17217
doi: 10.1073/pnas.190335897
Vollers, S. S. & Stern, L. J. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 123, 305–313 (2008).
pubmed: 18251991
pmcid: 2433336
doi: 10.1111/j.1365-2567.2007.02801.x
Nepom, G. T. MHC class II tetramers. J. Immunol. 188, 2477–2482 (2012).
pubmed: 22389204
doi: 10.4049/jimmunol.1102398
Wooldridge, L. et al. Tricks with tetramers: how to get the most from multimeric peptide–MHC. Immunology 126, 147–164 (2009).
pubmed: 19125886
pmcid: 2632693
doi: 10.1111/j.1365-2567.2008.02848.x
Zhao, W. & Sher, X. Systematically benchmarking peptide–MHC binding predictors: from synthetic to naturally processed epitopes. PLoS Comput. Biol. 14, e1006457 (2018).
pubmed: 30408041
pmcid: 6224037
doi: 10.1371/journal.pcbi.1006457
Wang, X. X. et al. Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4–HLA-DR1 complex. Proc. Natl Acad. Sci. USA 108, 15960–15965 (2011).
pubmed: 21900604
pmcid: 3179091
doi: 10.1073/pnas.1109438108
Konig, R., Huang, L. Y. & Germain, R. N. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 356, 796–798 (1992).
pubmed: 1574118
doi: 10.1038/356796a0
Konig, R. Interactions between MHC molecules and co-receptors of the TCR. Curr. Opin. Immunol. 14, 75–83 (2002).
pubmed: 11790535
doi: 10.1016/S0952-7915(01)00300-4
Artyomov, M. N., Lis, M., Devadas, S., Davis, M. M. & Chakraborty, A. K. CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery. Proc. Natl Acad. Sci. USA 107, 16916–16921 (2010).
pubmed: 20837541
pmcid: 2947881
doi: 10.1073/pnas.1010568107
Solberg, O. D. et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum. Immunol. 69, 443–464 (2008).
pubmed: 18638659
pmcid: 2632948
doi: 10.1016/j.humimm.2008.05.001
Yamashita, Y. et al. HLA-DP
pubmed: 28489076
pmcid: 5436232
doi: 10.1038/ncomms15244
Anczurowski, M. et al. Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP
pubmed: 29555965
pmcid: 5859192
doi: 10.1038/s41598-018-22931-4
Pinto, E. M. et al. Prognostic significance of major histocompatibility complex class II expression in pediatric adrenocortical tumors: a St. Jude and Children’s Oncology Group study. Clin. Cancer Res. 22, 6247–6255 (2016).
pubmed: 27307598
pmcid: 5159323
doi: 10.1158/1078-0432.CCR-15-2738
Yao, X. et al. Isolation and characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T-cell receptor for cancer immunotherapy. J. Immunother. 39, 191–201 (2016).
pubmed: 27163739
pmcid: 4947411
doi: 10.1097/CJI.0000000000000123
Lu, Y. C. et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J. Clin. Oncol. 35, 3322–3329 (2017).
pubmed: 28809608
pmcid: 5652397
doi: 10.1200/JCO.2017.74.5463
Merkel, P. A. et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 69, 1054–1066 (2017).
pubmed: 28029757
pmcid: 5434905
doi: 10.1002/art.40034
Lamprecht, P. et al. Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front. Immunol. 9, 680 (2018).
pubmed: 29686675
pmcid: 5900791
doi: 10.3389/fimmu.2018.00680
Hilhorst, M. et al. HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study. Arthritis Rheumatol. 68, 1721–1730 (2016).
pubmed: 26866715
doi: 10.1002/art.39620
Williams, T. M. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J. Mol. Diagn. 3, 98–104 (2001).
pubmed: 11486048
pmcid: 1906958
doi: 10.1016/S1525-1578(10)60658-7
Melenhorst, J. J. et al. Detection of low avidity CD8
pubmed: 18675271
pmcid: 2714739
doi: 10.1016/j.jim.2008.07.008
Wooldridge, L. et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor–antigen complexes at the cell surface. J. Biol. Chem. 280, 27491–27501 (2005).
pubmed: 15837791
doi: 10.1074/jbc.M500555200
Wooldridge, L. et al. MHC class I molecules with superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J. Immunol. 184, 3357–3366 (2010).
pubmed: 20190139
doi: 10.4049/jimmunol.0902398
Butler, M. O. et al. Ex vivo expansion of human CD8
pubmed: 22279573
pmcid: 3257268
doi: 10.1371/journal.pone.0030229
Heemskerk, M. H. et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102, 3530–3540 (2003).
pubmed: 12869497
doi: 10.1182/blood-2003-05-1524
Straetemans, T. et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin. Dev. Immunol. 2012, 586314 (2012).
pubmed: 22400038
pmcid: 3287115
doi: 10.1155/2012/586314
Lin, Y. et al. HLA-DPB1*05:01-restricted WT1
pubmed: 23502763
doi: 10.1097/CJI.0b013e3182873581
Odunsi, K. et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA 104, 12837–12842 (2007).
pubmed: 17652518
pmcid: 1937553
doi: 10.1073/pnas.0703342104
Laurin, D. et al. Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-V
pubmed: 17085304
doi: 10.1016/j.bbmt.2006.07.012
Jones, C. M., Lake, R. A., Lamb, J. R. & Faith, A. Degeneracy of T cell receptor recognition of an influenza virus hemagglutinin epitope restricted by HLA-DQ and -DR class II molecules. Eur. J. Immunol. 24, 1137–1142 (1994).
pubmed: 7514130
doi: 10.1002/eji.1830240519
Hennecke, J., Carfi, A. & Wiley, D. C. Structure of a covalently stabilized complex of a human αβ T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J. 19, 5611–5624 (2000).
pubmed: 11060013
pmcid: 305780
doi: 10.1093/emboj/19.21.5611
Tsuji, T. et al. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4
pubmed: 22427632
doi: 10.4049/jimmunol.1103269
Neunkirchner, A. et al. Human TCR transgenic Bet v 1-specific Th1 cells suppress the effector function of Bet v 1-specific Th2 cells. J. Immunol. 187, 4077–4087 (2011).
pubmed: 21908735
doi: 10.4049/jimmunol.1003220
Benati, D. et al. Public T cell receptors confer high-avidity CD4 responses to HIV controllers. J. Clin. Invest. 126, 2093–2108 (2016).
pubmed: 27111229
pmcid: 4887161
doi: 10.1172/JCI83792
Nakatsugawa, M. et al. CD4
pubmed: 27030642
pmcid: 4814874
doi: 10.1038/srep23821
Nakatsugawa, M. et al. Specific roles of each TCR hemichain in generating functional chain-centric TCR. J. Immunol. 194, 3487–3500 (2015).
pubmed: 25710913
doi: 10.4049/jimmunol.1401717
Ochi, T. et al. Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy. Cancer Immunol. Res. 3, 1070–1081 (2015).
pubmed: 25943533
pmcid: 4561213
doi: 10.1158/2326-6066.CIR-14-0222
Hirano, N. et al. Engagement of CD83 ligand induces prolonged expansion of CD8
pubmed: 16239433
pmcid: 1895397
doi: 10.1182/blood-2005-05-2073
Butler, M. O. et al. Long-lived antitumor CD8
pubmed: 17363542
doi: 10.1158/1078-0432.CCR-06-1905
Hirano, N. et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin. Cancer Res. 12, 2967–2975 (2006).
pubmed: 16707591
doi: 10.1158/1078-0432.CCR-05-2791
Wooldridge, L. et al. Anti-coreceptor antibodies profoundly affect staining with peptide–MHC class I and class II tetramers. Eur. J. Immunol. 36, 1847–1855 (2006).
pubmed: 16783852
doi: 10.1002/eji.200635886
Hirano, N. et al. Identification of an immunogenic CD8
pubmed: 16778141
pmcid: 1895581
doi: 10.1182/blood-2006-04-017566
Imataki, O. et al. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8
pubmed: 22238455
doi: 10.4049/jimmunol.1003446
Su, L. F., Kidd, B. A., Han, A., Kotzin, J. J. & Davis, M. M. Virus-specific CD4
pubmed: 23395677
pmcid: 3626102
doi: 10.1016/j.immuni.2012.10.021
Bienert, S. et al. The SWISS-MODEL Repository—new features and functionality. Nucleic Acids Res. 45, D313–D319 (2017).
pubmed: 27899672
doi: 10.1093/nar/gkw1132
Bertoni, M., Kiefer, F., Biasini, M., Bordoli, L. & Schwede, T. Modeling protein quaternary structure of homo- and hetero-oligomers beyond binary interactions by homology. Sci. Rep. 7, 10480 (2017).
pubmed: 28874689
pmcid: 5585393
doi: 10.1038/s41598-017-09654-8
Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296–W303 (2018).
pubmed: 29788355
pmcid: 6030848